Clinical Trial Update: Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating topical spironolactone for preventing corticosteroid-induced epidermal atrophy; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucocorticoid-induced Skin Atrophy

Drugs mentioned

• Topical spironolactone (spironolactone)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Cutaneous Atrophy Due to Corticosteroids | Phase 2 | Status: COMPLETED